Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Trudy H Grossman"'
Autor:
Changhui Guan, Peter J Larson, Elizabeth Fleming, Alexander P Tikhonov, Sara Mootien, Trudy H Grossman, Caroline Golino, Julia Oh
Publikováno v:
PLoS ONE, Vol 17, Iss 12, p e0276795 (2022)
The prevalence and virulence of pathogens such as methicillin-resistant Staphylococcus (S.) aureus (MRSA), which can cause recurrent skin infections, are of significant clinical concern. Prolonged antibiotic exposure to treat or decolonize S. aureus
Externí odkaz:
https://doaj.org/article/00e90a1dce214ab3a139f7b6090cc5f4
Autor:
David Dodds, Jeffrey L. Bose, Ming-De Deng, Gilles R. Dubé, Trudy H. Grossman, Alaina Kaiser, Kashmira Kulkarni, Roger Leger, Sara Mootien-Boyd, Azim Munivar, Julia Oh, Matthew Pestrak, Komal Rajpura, Alexander P. Tikhonov, Traci Turecek, Travis Whitfill
Publikováno v:
mSphere, Vol 5, Iss 3 (2020)
ABSTRACT Using live microbes as therapeutic candidates is a strategy that has gained traction across multiple therapeutic areas. In the skin, commensal microorganisms play a crucial role in maintaining skin barrier function, homeostasis, and cutaneou
Externí odkaz:
https://doaj.org/article/ba1d4abd99a34cf9a5fdc6d24226e084
Autor:
Trudy H. Grossman, Corey Fyfe, William O’Brien, Meredith Hackel, Mary Beth Minyard, Ken B. Waites, Jacques Dubois, Timothy M. Murphy, Andrew M. Slee, William J. Weiss, Joyce A. Sutcliffe
Publikováno v:
mSphere, Vol 2, Iss 1 (2017)
ABSTRACT TP-271 is a novel, fully synthetic fluorocycline antibiotic in clinical development for the treatment of respiratory infections caused by susceptible and multidrug-resistant pathogens. TP-271 was active in MIC assays against key community re
Externí odkaz:
https://doaj.org/article/fc839a5a5190439892aac4f57b1d746e
Autor:
Jeffrey L. Bose, Sara Mootien-Boyd, Alaina Kaiser, Matthew Pestrak, Ming-De Dong, Roger Leger, Trudy H. Grossman, Traci Turecek, Travis Whitfill, Azim Munivar, Gilles R. Dubé, Kashmira Kulkarni, Julia Oh, Alexander P. Tikhonov, Komal Rajpura, David R. Dodds
Publikováno v:
mSphere
mSphere, Vol 5, Iss 3 (2020)
mSphere, Vol 5, Iss 3, p e00360-20 (2020)
mSphere, Vol 5, Iss 3 (2020)
mSphere, Vol 5, Iss 3, p e00360-20 (2020)
The skin microbiome is rich in opportunities for novel therapeutics for skin diseases, and synthetic biology offers the advantage of providing novel functionality or therapeutic benefit to live biotherapeutic products. The development of novel bacter
Autor:
L. A. McDermott, Kathy Kerstein, Joyce A. Sutcliffe, David R. Snydman, Trudy H. Grossman, Nilda V. Jacobus
The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83355f8d1d6d402d47513ac986732403
https://europepmc.org/articles/PMC5923129/
https://europepmc.org/articles/PMC5923129/
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:2567-2571
Eravacycline is a novel broad-spectrum fluorocycline antibiotic being developed for a wide range of serious infections. Eravacycline was efficacious in mouse septicemia models, demonstrating 50% protective dose (PD 50 ) values of ≤1 mg/kg of body w
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:2446-2449
Eravacycline (formerly TP-434) was evaluated in vitro against pre-established biofilms formed by a uropathogenic Escherichia coli strain. Biofilms were eradicated by 0.5 μg/ml eravacycline, which was within 2-fold of the MIC for planktonic cells. In
Autor:
Trudy H. Grossman, Winston Lin, Melanie Gooldy, Kaylyn Siefkas-Patterson, Lisa N. Henning, Michael S. Anderson, Lindsay Drabek, Anne K. Radcliff, Henry S. Heine, Joyce A. Sutcliffe, Rene Nevarez, Joseph V. Newman
The fluorocycline TP-271 was evaluated in mouse and nonhuman primate (NHP) models of inhalational anthrax. BALB/c mice were exposed by nose-only aerosol to Bacillus anthracis Ames spores at a level of 18 to 88 lethal doses sufficient to kill 50% of e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4834e07eaf89c1eb0cd3b1c514095623
https://europepmc.org/articles/PMC5610513/
https://europepmc.org/articles/PMC5610513/
Autor:
Joyce A. Sutcliffe, Kaylyn Siefkas-Patterson, Melanie Gooldy, Trudy H. Grossman, Anne K. Radcliff, Vincent H. Tam, Winston Lin, Lisa N. Henning, Henry S. Heine, M. Victoria Kindt, Michael S. Anderson, David Christ
TP-271 is a novel, fully synthetic fluorocycline in development for complicated bacterial respiratory infections. TP-271 was active in vitro against a panel of 29 Francisella tularensis isolates, showing MICs against 50% and 90% of isolates of 0.25 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c43b13ea72752325345e645ae307f6a
https://europepmc.org/articles/PMC5527625/
https://europepmc.org/articles/PMC5527625/
Autor:
Trudy H. Grossman, Joyce A. Sutcliffe, Corey Fyfe, Roger B. Clark, Xiao-Yi Xiao, Yonghong Deng, Diana K. Hunt, Chi-Li Chen, Cuixiang Sun
Publikováno v:
The Journal of antibiotics. 71(2)
A convergent total synthesis platform led to the discovery of TP-2758 from a series of novel 7-methoxy-8-heterocyclyl tetracycline analogs. TP-2758 demonstrated high in vitro potency against key Gram-negative pathogens including extended spectrum β-